TABLE 3.

Participants still on monotherapy by end of specified visit

All participants
Group	At randomization N = 491	At visit 1 N = 366	At visit 2 N = 299	At visit 3 N = 259
Chlorthalidone standard	84	62	54	47
Chlorthalidone intensive	126	75	47	33
Amlodipine standard	176	162	152	140
Amlodipine intensive	105	67	46	39

Antihypertensive treatment‐naive participants
Group	At randomization N = 246	At visit 1 N = 162	At visit 2 N = 117	At visit 3 N = 91
Chlorthalidone standard	68	47	39	33
Chlorthalidone intensive	108	62	37	26
Amlodipine standard	30	28	26	22
Amlodipine intensive	40	25	15	10